drugset / Trial / NCT03110588
Phase I Trial of PACE for Metastatic Prostate Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
This trial is being conducted to determine the feasibility and recommended dose of the combination of four drugs (prednisone, abiraterone, cabazitaxel and enzalutamide (PACE) as first-line therapy for metastatic castration-resistant prostate cancer (mCRPC).
Timeline
- Start
- 2018-05-09
- Primary completion
- 2019-12-18
- Completion
- 2019-12-18
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cabazitaxel | Other / unclassified | 15 mg/m2 | Intravenous |
| Subject | Cabazitaxel | Other / unclassified | 20 mg/m2 | Intravenous |
| Background | Abiraterone acetate | Small molecule | 1000 mg | Oral |
| Background | Enzalutamide | Other / unclassified | 160 mg | Oral |
| Background | Prednisone | Other / unclassified | 5 mg | Oral |